Clinical trials: Metabolic Control
Obesity
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of…
- Trial name
- NCT02229214
- Testing
- Qsymia
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Hypercholesterolemia
LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe
Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue.
- Trial name
- NCT00677248
- Testing
- Eprotirome and ezetimibe
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Karo Bio AB
Obesity
A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)
The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study…
- Trial name
- NCT00796367
- Testing
- VI-0521
- Volunteers
- 676 people
- Sponsor
- VIVUS LLC
Dementia, Frontotemporal
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants
This is a Phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of VES001 in a two part followed by a…
- Trial name
- SORT-IN-1 (NCT06226064)
- Testing
- VES001
- Where
- Netherlands
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Vesper Biotechnologies ApS
Metabolic Syndrome, Dyslipidemia
Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism
The purpose of this study is to investigate if daily consumption of barley beta-glucans effect lipid and glucose metabolism and alter intestinal microbiota composition in participants with metabolic syndrome or with high risk for…
- Conditions
- Metabolic Syndrome, Dyslipidemia, Obesity, Abdominal, Hyperglycemia
- Trial name
- NCT02041104
- Testing
- Bread with added beta-glucans
- Where
- 3 sites in Slovenia
- Volunteers
- 51 people
- Sponsor
- Mlinotest Zivilska Industrija d.d.
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis
Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Metabolic Syndrome
- Trial name
- Aramchol003 (NCT01094158)
- Testing
- Aramchol
- Where
- 11 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Galmed Medical Reserch
Diabetes, Diabetes Mellitus, Type 2
Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes
This trial is conducted in the United States of America (USA). This trial compares the changes in HbA1c after 26 weeks of repaglinide and metformin fixed dose combination tablet given as twice daily versus three times daily…
- Trial name
- NCT00399711
- Testing
- repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet
- Where
- 103 sites in United States, Puerto Rico
- Volunteers
- 560 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study of Technology to Improve Glucose Control in Participants With Type 1 Diabetes
The main purpose of this study is to determine whether combining meal, glucose, and insulin data in a web-based system will improve management of type 1 diabetes (T1D). No study drug will be given.
- Trial name
- NCT03758430
- Testing
- Meal-Tagging App, Fitness Tracker
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Type I Diabetes
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.
- Trial name
- NCT06964087
- Testing
- OPT101
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Op-T LLC
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 2 (NCT05259033)
- Testing
- IcoSema, Semaglutide 1 mg
- Where
- 193 sites in United States, Brazil and 13 more
- Volunteers
- 683 people
- Sponsor
- Novo Nordisk A/S
Hyperlipidemias
Effect of ANKASCIN 568-P Products Regulating Blood Lipid
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
- Trial name
- NCT05737355
- Testing
- ANKASCIN 568-P Red yeast rice capsules
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- SunWay Biotech Co., LTD.
Obesity
Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity
The purpose of this study is to determine the efficacy and safety of 3 combinations of naltrexone and bupropion SR compared to naltrexone alone, bupropion SR alone or placebo.
- Trial name
- NCT00364871
- Testing
- naltrexone and bupropion SR
- Where
- 7 sites in United States
- Volunteers
- 410 people
- Sponsor
- Orexigen Therapeutics, Inc
Diabete Type 2, Obesity
Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled parallel group study of HU6 and placebo in subjects who are overweight or obese with T2D. The study will be conducted in 4 stages.
- Trial name
- NCT06104358
- Testing
- HU6
- Where
- United States
- Sponsor
- Rivus Pharmaceuticals, Inc.
Hypercholesterolemia
Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin
The primary purpose of this placebo-controlled study is to evaluate the low-density lipoprotein cholesterol (LDL-C) efficacy and dose-response of gemcabene 300, 600 and 900 mg/day administered as monotherapy or in combination…
- Trial name
- NCT02591836
- Testing
- Gemcabene, Atorvastatin
- Volunteers
- 277 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Non-Alcoholic Fatty Liver Disease
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota…
- Trial name
- CARDIO-LIVER (NCT06704321)
- Testing
- TOTUM-448
- Where
- Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Amyotrophic Lateral Sclerosis
Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)
This was a parallel treatment, Phase 2, randomized, double-blind study to assess the efficacy, safety, tolerability, PK, and PD of twice daily (BID) oral SAR443820 compared with placebo in male and female participants, 18 to 80…
- Trial name
- HIMALAYA (NCT05237284)
- Testing
- SAR443820
- Where
- 63 sites in United States, Belgium and 11 more
- Volunteers
- 305 people
- Sponsor
- Sanofi
Severe Hypertriglyceridemia
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
- Trial name
- NCT05079919
- Testing
- Olezarsen
- Where
- 209 sites in United States, Australia and 21 more
- Volunteers
- 617 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Metabolic Syndrome, Diabetes Mellitus, Type 2
Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies
Original research article entitled Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome by Madeline Gibas for consideration for publication in a clinical journal.
- Conditions
- Metabolic Syndrome, Diabetes Mellitus, Type 2, Pre Diabetes
- Trial name
- NCT03047447
- Testing
- Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristlecone Behavioral Health, Inc.
Hyperlipidemia
A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
The study is being conducted to evaluate the efficacy, and safety of SHR-1918 in reducing serum low-density lipoprotein cholesterol (LDL-C) and total triglycerides (TG) in patients with hyperlipidemia compared with placebo, and…
- Trial name
- NCT07230730
- Testing
- SHR-1918
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Involutional Osteoporosis
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.
- Trial name
- NCT00212628
- Testing
- Minodronic acid hydrate
- Where
- 9 sites in Japan
- Volunteers
- 444 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.